Biotech Values

[JohnWayne]

For example, what competent analyst(one who's generally familiar with the cml field) could concur for a second with the idea that Bosulif could become a preferred front-line therapy in cml? Assuming they know enough to realize how unlikely that is, you would expect more than an endorsement of such an idea(despite the minor qualification), when they should be more seriously questioning their survey methodology.

Can you quote the part of the report where CS says that Bosulif could become a preferred front-line therapy?

And also, it's important to understand that just because an ambiguity hasn't been interpreted in the most optimistic/bullish way possible, doesn't mean it's a skewed interpretation.

FWIW I am long ARIA and I don't really take issue with the CS report. I don't agree with it all, but it doesn't come across as misleading to me.